This article focuses on a specific ICI – Immune Checkpoint Inhibitor Strategy: Ipilimumab and Keytruda
Ask Your Doctor to Look For:
Copy and Paste the content below and email it to your Doctor.
IF IHC Test: (Immunohistochemistry)
A 3-5 panel test that stains the tissue to identify key biomarkers. These markers can indicate how well immunotherapy might work. Please request the following tests:
- PD-L1 (Programmed Death-Ligand 1):
Request testing for PD-L1 expression and provide the expression level as a percentage of tumor cells that express PD-L1. This helps determine eligibility for PD-1/PD-L1 inhibitors (e.g., Keytruda). The Combined Positive Score (CPS) is commonly used. - Mismatch Repair (MMR) Deficiency:
Request testing for MMR deficiency by assessing the expression of key proteins: MLH1, PMS2, MSH2, and MSH6. Loss of these proteins may indicate dMMR (deficient MMR), which is predictive of response to immunotherapy. - Microsatellite Instability (MSI):
Ask to determine the tumor’s MSI status—whether it is MSI-High, MSI-Low, or MSS (Microsatellite Stable). MSI-H indicates higher likelihood of response to immunotherapy, while MSS suggests a stable genetic environment. - HER2 (Human Epidermal Growth Factor Receptor 2) (if applicable):
Request HER2 testing to determine if the tumor overexpresses HER2, which may allow for HER2-targeted therapies (e.g., trastuzumab). - CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) (if considering combination immunotherapy):
Request CTLA-4 expression analysis on immune cells (e.g., regulatory T cells (Tregs)) to assess whether CTLA-4 blockade (e.g., ipilimumab) might be beneficial in combination with PD-1 inhibitors.
IF Molecular Profiling (Duration: 4–6 weeks):
A comprehensive test that analyzes the genetic mutations in the tumor and immune environment. It provides deeper insights into the most effective targeted and immunotherapy treatments. Please request the following tests:
- PD-L1 (Programmed Death-Ligand 1):
Request testing for PD-L1 expression and provide the percentage of tumor cells expressing PD-L1 (using CPS if possible). This helps guide treatment with PD-1/PD-L1 inhibitors (e.g., Keytruda). - TMB (Tumor Mutational Burden):
Ask for TMB analysis to assess whether the tumor is TMB-High or TMB-Low. TMB-High tumors tend to respond better to immunotherapy because they generate more neoantigens that stimulate the immune response. - Mismatch Repair (MMR) Status:
Request testing for MMR deficiency in genes like MLH1, PMS2, MSH2, and MSH6. Deficiency in these genes (dMMR) is associated with MSI-High tumors, which are more likely to respond to immunotherapy. MSS (Stable) indicates normal MMR function. - MSI (Microsatellite Instability):
Ask for MSI status to determine if the tumor is MSI-High or MSI-Low. MSI-High tumors tend to have more mutations and respond better to immunotherapy. - Actionable Mutations:
Request profiling of genetic mutations that are associated with targeted therapies, including:- FGFR2 (Fibroblast Growth Factor Receptor 2): Common in cholangiocarcinoma and targeted by FGFR inhibitors.
- IDH1/IDH2 (Isocitrate Dehydrogenase 1/2): Mutations may be treatable with IDH inhibitors.
- KRAS, BRCA1, BRCA2: These mutations influence prognosis and guide therapy in many cancers.
- HER2/ERBB2: May allow for HER2-targeted treatments.
- BRAF (e.g., V600E mutation): Can guide the use of BRAF/MEK inhibitors.
- TP53: While not directly targetable, it provides insight into the overall tumor biology.
Glossary of Terms
- Antigen-Presenting Cells (APCs): Cells that capture harmful invaders (antigens) and present them to T-cells, instructing the immune system to attack.
- CD28: A protein on T-cells that acts like an “accelerator pedal,” helping to activate T-cells when they receive a signal from antigen-presenting cells.
- CTLA-4: A protein that acts as a brake on T-cells, preventing them from becoming too active. When blocked by drugs like Ipilimumab, it allows T-cells to become more aggressive against cancer cells.
- dMMR (Deficient Mismatch Repair): A condition where a cell’s DNA repair system is broken, allowing many DNA errors to build up. These errors make the cancer more visible to the immune system.
- Immune Checkpoint Inhibitors (ICIs): Drugs that block proteins like CTLA-4 and PD-1, which cancer cells use to hide from the immune system. By blocking these proteins, ICIs enable the immune system to attack cancer cells.
- Ipilimumab: An immunotherapy drug that blocks the CTLA-4 checkpoint, allowing T-cells to attack cancer cells more aggressively.
- Keytruda (Pembrolizumab): An immunotherapy drug that blocks the PD-1 checkpoint, preventing cancer cells from using PD-L1 to hide from the immune system.
- MSI-High (Microsatellite Instability-High): A condition where cancer cells have a lot of DNA errors due to a malfunctioning DNA repair system (dMMR). This leads to the production of more neoantigens, making the cancer more noticeable to the immune system.
- Neoantigens: Malformed proteins created by cancer cells due to DNA mutations. These abnormal proteins alert the immune system, making the tumor more visible.
- PD-1: A checkpoint protein on T-cells that interacts with PD-L1 to deactivate T-cells, preventing them from attacking healthy cells. Cancer cells often exploit this interaction to avoid being attacked.
- PD-L1: A protein found on the surface of normal and cancer cells that binds to PD-1 on T-cells to deactivate the immune response. Some cancers overproduce PD-L1 to hide from the immune system.
- T-cells: The immune system’s “patrol officers.” They are responsible for identifying and attacking harmful invaders, like bacteria, viruses, and cancer cells.
- TMB-High (Tumor Mutational Burden-High): A tumor with many genetic mutations, which creates neoantigens and makes the cancer easier for the immune system to detect and attack.
The Checkpoint Pathway: The Immune System’s Central Command
Science Steps in to Support Central Command With Ipilimumab and Keytruda Strike Force
What Goes Wrong in Cancer
In a healthy immune system, T-cells are tightly regulated by two checkpoint systems:
- CD28/CTLA-4, which controls T-cell activation (the signal that tells T-cells what and when to attack). CD28 normally binds with antigen-presenting cells (APCs), which collect information about foreign invaders like viruses, bacteria, and cancer cells. The APCs present this information to T-cells by binding to CD28, which activates the T-cells. However, CTLA-4 competes with CD28 for binding to the APCs. When CTLA-4 becomes too dominant, it prevents T-cell activation, acting as a brake on the immune response.
- PD-1/PD-L1, which controls T-cell deactivation (the signal that tells T-cells when to stop attacking). PD-L1 binds to PD-1 on T-cells, sending the “stop” signal, ensuring the immune system doesn’t attack healthy tissues.
These checkpoints act like traffic lights for T-cells, ensuring they only attack harmful invaders, like bacteria or cancer cells, and don’t mistakenly harm normal, healthy cells.
PD-L1’s Job in a Healthy System
PD-L1 is a protein found on the surface of many normal cells. Its primary job is to signal to T-cells—the immune system’s patrol officers—that the cell is healthy and should not be attacked.
How it works: PD-L1 on a healthy cell binds to the PD-1 receptor on an approaching T-cell. This binding sends a signal to deactivate the T-cell’s attack, preventing the immune system from mistakenly harming healthy tissues.
MSI-High: Disrupted Checkpoints Due to DNA Errors
In cancer cells with Microsatellite Instability-High (MSI-High), the genes suffer significant damage, which disrupts their normal function and the regulation of PD-L1 production. This can lead to overproduction (overexpression) of PD-L1 on the surface of cancer cells. These cancer cells constantly send “don’t attack” signals to T-cells, allowing the cancer to evade immune detection.
Hot Tumor vs. Cold Tumor: A Loud Party vs. A Quiet Party
- Hot Tumor (Loud Party): A hot tumor is like a loud party that draws the attention of the immune system. MSI-High and TMB-High cancers are considered hot tumors because they are full of neoantigens—abnormal, malformed proteins—like a party packed with loud, obnoxious guests. This loud activity grabs the immune system’s attention, signaling it to respond. However, the tumor counters this by producing an overwhelming amount of PD-L1 proteins, which act as a shield, telling T-cells not to attack despite the chaos. This creates a major obstacle for the immune system, but it also exposes a vulnerability that science has figured out how to exploit.
- Cold Tumor (Quiet Party): In contrast, a cold tumor is like a quiet party that goes unnoticed by the immune system. These tumors have fewer mutations and produce fewer neoantigens (obnoxious guests), making them less likely to attract T-cell attention. As a result, the immune system doesn’t see or hear them, failing to recognize them as a threat, allowing the tumor to continue growing with stealth.
How Understanding This Helps
Understanding whether a tumor is hot or cold is important because it influences how the tumor responds to treatments like immune checkpoint inhibitors. Hot tumors—like those that are MSI-High or TMB-High—are often more responsive to treatments like PD-1 inhibitors because the immune system is already somewhat aware of the tumor. Cold tumors, on the other hand, might require treatments that “heat up” the tumor by attracting the immune system’s attention.
Tumor Types Summary:
- Hot tumors are like loud parties that attract the attention of the immune system, often seen in MSI-High and TMB-High cancers, making them more likely to respond to immune checkpoint inhibitors.
- Cold tumors are like quiet parties that go unnoticed by the immune system, requiring additional strategies to make them more visible and responsive to treatment.
How Science Figured Out the Weakness of Hot MSI-High Tumors
Once researchers understood how hot tumors like MSI-High cancers use PD-L1 overexpression to evade the immune system, they found a way to turn this defense mechanism into a weakness.
PD-L1 acts as a shield for the tumor, deactivating T-cells and preventing them from attacking. But this very strategy—overproducing PD-L1—opened up a potential solution: if scientists could block the PD-L1/PD-1 interaction, the immune system could regain its ability to attack the tumor.
PD-1 Inhibitors: Unlocking the Attack
By developing PD-1 inhibitors, such as Keytruda, researchers created a way to block PD-L1 from binding to PD-1 on T-cells. Think of these inhibitors as a cover that prevents PD-L1 from sending its “don’t attack” signal to the T-cells.
Once the PD-1/PD-L1 interaction is blocked, the T-cells are no longer deactivated and can launch their attack on the tumor. This allows the immune system to break through the tumor’s defense and fight back.
Why This Works in Hot MSI-High Tumors
MSI-High tumors are packed with neoantigens, which makes them more noticeable to the immune system. When the PD-L1 shield is lifted, the immune system can now recognize these abnormal proteins and mount a stronger attack. PD-1 inhibitors have been particularly successful in treating MSI-High and TMB-High cancers because these tumors rely heavily on PD-L1 overexpression to hide from the immune system. Removing that protection exposes the tumor to immune destruction.
How This Helps Patients
For patients with MSI-High or TMB-High cancers, PD-1 inhibitors offer a powerful treatment option. By blocking the cancer’s ability to deactivate T-cells, these therapies give the immune system the chance to recognize and attack the cancer, making hot tumors much more vulnerable to immune-based treatments.
Ipilimumab and Keytruda: A Strategic Immunotherapy Strike Force
Once you understand how the Checkpoint Pathway works and how cancer takes advantage of it, you can see why Ipilimumab and Keytruda are such powerful immunotherapy tools. These two drugs work together to remove the brakes and disguises that cancer cells are able to utilize to essentially hide from the immune system, allowing the body to launch a full-scale attack on the cancer.
How Ipilimumab Works
Our immune system uses T-cells to patrol the body, seeking out and eliminating harmful invaders, such as bacteria, viruses, and cancer cells. However, the CTLA-4 checkpoint acts like a brake on these T-cells, preventing them from becoming fully activated.
Ipilimumab is designed to block the CTLA-4 checkpoint, essentially releasing the brake. Once CTLA-4 is blocked, CD28 is free to bind with the APC (Antigen-Presenting Cell), which presents evidence of the invader (such as a cancer cell) to the T-cells. This binding activates the T-cells, allowing them to respond more aggressively to cancer cells and other threats, boosting the immune system’s overall attack.
How Keytruda Works
Keytruda works by blocking the PD-1 receptor on T-cells, effectively removing the cancer’s ability to use PD-L1 to evade the immune system’s attack. With the PD-1/PD-L1 interaction blocked, the preactivated T-cell has no other option but to attack and eliminate the previously hidden cancer cell. This empowers the immune system’s information loop, prompting more T-cells to seek out and destroy other cancer cells.
Why This Strategic Combination Could Be Very Effective
By combining Ipilimumab and Keytruda, you’re addressing two critical junctures in the checkpoint pathway—T-cell activation and T-cell deactivation—both of which cancer cells exploit to evade the immune system:
- Ipilimumab removes the brake on T-cells, allowing them to become fully activated and more aggressive in their response.
- Keytruda removes the deactivation mechanism (the “stop sign”) that cancer cells use to disguise themselves, enabling the immune system to recognize and attack them.
This combination can be especially effective in cancers with specific characteristics like dMMR (deficient Mismatch Repair), MSI-High (Microsatellite Instability-High), PD-L1 overexpression, or TMB-High (Tumor Mutational Burden-High). These tumors are often more vulnerable to immunotherapy because they rely heavily on checkpoint pathways to avoid immune detection.
What is dMMR (Deficient Mismatch Repair)?
The Mismatch Repair (MMR) system is your body’s DNA spellchecker. It identifies and fixes errors that occur when cells divide and replicate their DNA. The MMR system relies on several key genes, including MLH1, PMS2, MSH2, and MSH6. When one or more of these genes is missing or not functioning correctly, this leads to deficient Mismatch Repair (dMMR).
- dMMR with MSI-Low: When one gene (like MLH1 or PMS2) is missing or defective, it leads to a lower number of DNA errors, known as MSI-Low (Microsatellite Instability-Low).
- dMMR with MSI-High: When two or more genes, such as MLH1 and PMS2, are absent or dysfunctional, the number of DNA replication errors increases significantly. This leads to MSI-High (Microsatellite Instability-High), where the DNA becomes highly unstable. This instability causes the production of many abnormal proteins (neoantigens), making the cancer more visible to the immune system.
In tumors with dMMR and MSI-High, the high number of mutations makes the cancer more likely to be recognized by the immune system, which is why these tumors tend to respond well to immunotherapy treatments like Ipilimumab and Keytruda.
Understanding the Role of dMMR, MSI-High, PD-L1, and TMB-High
These factors explain why some tumors respond better to immunotherapy, particularly the combination of Ipilimumab and Keytruda:
- dMMR (deficient Mismatch Repair): The MMR system is responsible for fixing mistakes in a cell’s DNA. When this system is broken (dMMR), the DNA accumulates errors, leading to Microsatellite Instability. Tumors with dMMR are more visible to the immune system because they produce more abnormal proteins (neoantigens), making them more likely to respond to immunotherapy.
- MSI-High (Microsatellite Instability-High): MSI-High tumors have a large number of DNA errors because the MMR system is defective. This creates an abundance of abnormal proteins (neoantigens), which makes the tumor more detectable by the immune system.
- PD-L1 expression: Some tumors produce high levels of PD-L1, the “stop sign” that tells the immune system not to attack. By blocking PD-1 with Keytruda, this stop sign is removed, allowing the immune system to attack the tumor.
- TMB-High (Tumor Mutational Burden-High): TMB-High tumors accumulate many mutations, which makes them more recognizable by the immune system. Like MSI-High tumors, these cancers are often more responsive to immunotherapy.
Join Light Australia Green 2025
Projects you are supporting
Optimal Patient Response (OPR)
From Passenger To Co-Pilot: An Initiative and a carefully choreographed process that enhances healthcare by transforming the standard-of-care into a more comprehensive ‘standard-of-response’ process. At its core are printed Patient Navigator Journals and supporting digital web-app suite, all designed to better equip and empower the patients capacity to effectively respond and survive their diagnosis. A clear, step-by-step process supported by CCF peer-trained Navigators, Coaches, Hospital Coordinators, and a constructive peer-to-peer community, replacing chaos with calm, and overwhelm with direction.
Light Australia Green
Galvanising Collaboration: The Light Australia Green Initiative is a comprehensive annual campaign focused on raising awareness and driving engagement in bile health and cancer response. Through targeted events, such as hospital-hosted symposiums, landmark illuminations on World Cholangiocarcinoma Day, and an annual conference, the initiative unites key stakeholders to promote collaboration, education and progress in managing bile-related cancers.
